L-TIL Plus Tislelizumab for PD1 Antibody Resistant aNSCLC

The goal of this observational study is to test in advanced non-small cell lung cancer patients with negative driver gene. For these patients, PD1 antibody therapy combined with chemotherapy was the preferred regimen. However, there is no standard regimen for the patients who refractory from the first-line PD1 inhibitor based therapy. The main questions they aim to answer are: 1.The efficacy of Liquid Tumor Infiltrating Lymphocytes (L-TIL) plus Tislelizumab and Docetaxel for patients failure from first line chemotherapy and PD1 inhibitor therapy. 2. The safety of L-TIL plus Tislelizumab and D

Trial Details

NCT ID
NCT05878028
Phase
PHASE2
Sponsor
Quanli Gao
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • L-TIL, Tislelizumab, Docetaxel
Locations (sample)
  • Zhengzhou, Henan, China|34.75778,113.64861

Key Eligibility Criteria

  • Non-small cell lung cancer patients diagnosed by pathological histology.
  • Imaging examination showed stage IV disease.
  • Non-squamous cancer patients shall be EGFR , ALK, ROS1, RET, MET negative.
  • Failure from anti-PD-1 antibody treatment, including treatment ineffective or effective for a period then progress.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →